Profil
Raymond Kaempfer was the founder of Atox Bio Ltd., which was founded in 2003, where he held the title of Chief Scientific Officer from 2003 to 2011.
He is currently a Member of the European Molecular Biology Organization.
Dr. Kaempfer's former positions include being a Faculty Member at Harvard University and a Professor of Molecular Biology & Cancer Research at The Hebrew University of Jerusalem.
Dr. Kaempfer received a doctorate degree from the Massachusetts Institute of Technology.
Aktiva positioner av Raymond Kaempfer
| Företag | Position | Start |
|---|---|---|
European Molecular Biology Organization | Företagsledare/Principal | - |
Tidigare kända positioner av Raymond Kaempfer
| Företag | Position | Slut |
|---|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Grundare | - |
Raymond Kaempfers utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
European Molecular Biology Organization | |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
















